• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型血管紧张素Ⅱ受体拮抗剂 Fimasartan 对自发性高血压大鼠肾上腺髓质儿茶酚胺释放的影响。

Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats.

机构信息

Department of Internal Medicine, School of Medicine, Seoul National University, Seoul 710-744, Korea.

出版信息

Korean J Physiol Pharmacol. 2013 Feb;17(1):99-109. doi: 10.4196/kjpp.2013.17.1.99. Epub 2013 Feb 14.

DOI:10.4196/kjpp.2013.17.1.99
PMID:23441003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3579112/
Abstract

The aim of this study was to determine whether fimasartan, a newly developed AT(1) receptor blocker, can affect the CA release in the isolated perfused model of the adrenal medulla of spontaneously hypertensive rats (SHRs). Fimasartan (5~50 µM) perfused into an adrenal vein for 90 min produced dose- and time-dependently inhibited the CA secretory responses evoked by ACh (5.32 mM), high K(+) (56 mM, a direct membrane depolarizer), DMPP (100 µM) and McN-A-343 (100 µM). Fimasartan failed to affect basal CA output. Furthermore, in adrenal glands loaded with fimasartan (15 µM), the CA secretory responses evoked by Bay-K-8644 (10 µM, an activator of L-type Ca(2+) channels), cyclopiazonic acid (10 µM, an inhibitor of cytoplasmic Ca(2+)-ATPase), and veratridine (100 µM, an activator of Na(+) channels) as well as by angiotensin II (Ang II, 100 nM), were markedly inhibited. In simultaneous presence of fimasartan (15 µM) and L-NAME (30 µM, an inhibitor of NO synthase), the CA secretory responses evoked by ACh, high K(+), DMPP, Ang II, Bay-K-8644, and veratridine was not affected in comparison of data obtained from treatment with fimasartan (15 µM) alone. Also there was no difference in NO release between before and after treatment with fimasartan (15 µM). Collectively, these experimental results suggest that fimasartan inhibits the CA secretion evoked by Ang II, and cholinergic stimulation (both nicotininc and muscarinic receptors) as well as by membrane depolarization from the rat adrenal medulla. It seems that this inhibitory effect of fimasartan may be mediated by blocking the influx of both Na(+) and Ca(2+) through their ion channels into the rat adrenomedullary chromaffin cells as well as by inhibiting the Ca(2+) release from the cytoplasmic calcium store, which is relevant to AT(1) receptor blockade without NO release.

摘要

本研究旨在探讨新型血管紧张素Ⅱ受体拮抗剂(AT1 受体拮抗剂)非那司他对自发性高血压大鼠(SHR)肾上腺髓质嗜铬细胞(CA)释放的影响。非那司他(5~50 μM)经肾上腺静脉持续灌注 90min,呈浓度和时间依赖性地抑制乙酰胆碱(ACh,5.32mM)、高钾(56mM,直接去极化)、二甲基吡咯烷酮(DMPP,100μM)和 N-甲基乙酰胆碱(McN-A-343,100μM)诱导的 CA 分泌反应。非那司他对基础 CA 释放无影响。此外,在预先给予非那司他(15 μM)的肾上腺中,Bay-K-8644(10 μM,L 型钙通道激动剂)、环匹阿尼酸(10 μM,胞浆钙泵抑制剂)和藜芦碱(100 μM,钠通道激动剂)以及血管紧张素Ⅱ(AngⅡ,100nM)诱导的 CA 分泌反应明显受抑制。预先给予非那司他(15 μM)和一氧化氮合酶抑制剂(L-NAME,30 μM),与单独给予非那司他(15 μM)相比,ACh、高钾、DMPP、AngⅡ、Bay-K-8644 和藜芦碱诱导的 CA 分泌反应无明显变化,且非那司他(15 μM)处理前后 NO 释放无差异。总之,这些实验结果表明非那司他抑制 AngⅡ、ACh 及去极化诱导的 CA 释放,其抑制作用可能通过阻断 Na+和 Ca2+通过离子通道流入大鼠肾上腺髓质嗜铬细胞及抑制胞浆钙库内 Ca2+释放而实现,这种作用与阻断 AT1 受体有关,与 NO 释放无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/fe6f7f923a09/kjpp-17-99-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/22fa24db125e/kjpp-17-99-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/ad20c82c4277/kjpp-17-99-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/000e16148a69/kjpp-17-99-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/f7842c4641f5/kjpp-17-99-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/6e2b29be83ed/kjpp-17-99-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/7bb84bd0d07b/kjpp-17-99-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/3cfa5dad15c8/kjpp-17-99-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/fe6f7f923a09/kjpp-17-99-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/22fa24db125e/kjpp-17-99-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/ad20c82c4277/kjpp-17-99-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/000e16148a69/kjpp-17-99-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/f7842c4641f5/kjpp-17-99-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/6e2b29be83ed/kjpp-17-99-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/7bb84bd0d07b/kjpp-17-99-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/3cfa5dad15c8/kjpp-17-99-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/3579112/fe6f7f923a09/kjpp-17-99-g008.jpg

相似文献

1
Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats.新型血管紧张素Ⅱ受体拮抗剂 Fimasartan 对自发性高血压大鼠肾上腺髓质儿茶酚胺释放的影响。
Korean J Physiol Pharmacol. 2013 Feb;17(1):99-109. doi: 10.4196/kjpp.2013.17.1.99. Epub 2013 Feb 14.
2
Effects of losartan on catecholamine release in the isolated rat adrenal gland.氯沙坦对离体大鼠肾上腺儿茶酚胺释放的影响。
Korean J Physiol Pharmacol. 2009 Aug;13(4):327-35. doi: 10.4196/kjpp.2009.13.4.327. Epub 2009 Aug 31.
3
Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla.奥美沙坦对灌流大鼠肾上腺髓质儿茶酚胺分泌的抑制作用。
Korean J Physiol Pharmacol. 2010 Aug;14(4):241-8. doi: 10.4196/kjpp.2010.14.4.241. Epub 2010 Aug 31.
4
Inhibitory Effects of Total Ginseng Saponin on Catecholamine Secretion from the Perfused Adrenal Medulla of SHRs.总人参皂苷对 SHR 灌流肾上腺髓质儿茶酚胺分泌的抑制作用。
J Ginseng Res. 2011 Jun;35(2):176-90. doi: 10.5142/jgr.2011.35.2.176.
5
Provinol inhibits catecholamine secretion from the rat adrenal medulla.普罗碘铵抑制大鼠肾上腺髓质儿茶酚胺的分泌。
Korean J Physiol Pharmacol. 2009 Jun;13(3):229-39. doi: 10.4196/kjpp.2009.13.3.229. Epub 2009 Jun 30.
6
Polyphenols of Rubus coreanum Inhibit Catecholamine Secretion from the Perfused Adrenal Medulla of SHRs.朝鲜蓟叶黄酮抑制 SHR 灌流肾上腺髓质儿茶酚胺的分泌。
Korean J Physiol Pharmacol. 2009 Dec;13(6):517-26. doi: 10.4196/kjpp.2009.13.6.517. Epub 2009 Dec 31.
7
Inhibitory effects of ginsenoside-rb2 on nicotinic stimulation-evoked catecholamine secretion.人参皂苷 -rb2 对烟碱刺激诱发的儿茶酚胺分泌的抑制作用。
Korean J Physiol Pharmacol. 2014 Oct;18(5):431-9. doi: 10.4196/kjpp.2014.18.5.431. Epub 2014 Oct 17.
8
Influence of lobeline on catecholamine release from the isolated perfused rat adrenal gland.洛贝林对离体灌注大鼠肾上腺髓质儿茶酚胺释放的影响。
Auton Neurosci. 2004 Jan 30;110(1):27-35. doi: 10.1016/j.autneu.2003.10.001.
9
Resveratrol inhibits nicotinic stimulation-evoked catecholamine release from the adrenal medulla.白藜芦醇抑制烟碱刺激引起的肾上腺髓质儿茶酚胺释放。
Korean J Physiol Pharmacol. 2008 Aug;12(4):155-64. doi: 10.4196/kjpp.2008.12.4.155. Epub 2008 Aug 31.
10
Influence of ketamine on catecholamine secretion in the perfused rat adrenal medulla.氯胺酮对灌流大鼠肾上腺髓质儿茶酚胺分泌的影响。
Korean J Physiol Pharmacol. 2008 Jun;12(3):101-9. doi: 10.4196/kjpp.2008.12.3.101. Epub 2008 Jun 30.

本文引用的文献

1
Fimasartan, a novel angiotensin II receptor antagonist.法米沙坦,一种新型的血管紧张素 II 受体拮抗剂。
Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z.
2
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.一项为期 12 周、多中心、前瞻性、随机、双盲、平行分组、剂量递增的 III 期临床试验,旨在比较新型血管紧张素受体阻滞剂菲玛沙坦与氯沙坦(50/100mg)在轻中度高血压成年韩国患者中的疗效和耐受性,该试验设有 12 周的可选扩展期。
Clin Ther. 2012 Mar;34(3):552-568, 568.e1-9. doi: 10.1016/j.clinthera.2012.01.024. Epub 2012 Mar 3.
3
The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.新型血管紧张素受体 II 拮抗剂非马沙坦对健康男性志愿者中 OATP1B1 相关阿托伐他汀药代动力学的影响。
J Cardiovasc Pharmacol. 2011 Nov;58(5):492-9. doi: 10.1097/FJC.0b013e31822b9092.
4
Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.新型血管紧张素Ⅱ受体拮抗剂菲玛沙坦与氨氯地平在健康志愿者体内的药代动力学相互作用。
J Cardiovasc Pharmacol. 2011 Jun;57(6):682-9. doi: 10.1097/FJC.0b013e31821795d0.
5
Inhibition of Ca2+ channels and adrenal catecholamine release by G protein coupled receptors.G 蛋白偶联受体对钙通道和肾上腺儿茶酚胺释放的抑制作用。
Cell Mol Neurobiol. 2010 Nov;30(8):1201-8. doi: 10.1007/s10571-010-9596-7.
6
Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla.奥美沙坦对灌流大鼠肾上腺髓质儿茶酚胺分泌的抑制作用。
Korean J Physiol Pharmacol. 2010 Aug;14(4):241-8. doi: 10.4196/kjpp.2010.14.4.241. Epub 2010 Aug 31.
7
Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.综述:血管紧张素 II 型 1 受体阻滞剂:类效应与分子效应。
J Renin Angiotensin Aldosterone Syst. 2011 Mar;12(1):1-7. doi: 10.1177/1470320310370852. Epub 2010 Jul 5.
8
Effects of losartan on catecholamine release in the isolated rat adrenal gland.氯沙坦对离体大鼠肾上腺儿茶酚胺释放的影响。
Korean J Physiol Pharmacol. 2009 Aug;13(4):327-35. doi: 10.4196/kjpp.2009.13.4.327. Epub 2009 Aug 31.
9
Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan.血管紧张素受体阻断的疗效:以奥美沙坦为对照的数据分析综述。
J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):147-56. doi: 10.1177/1470320309342735. Epub 2009 Aug 3.
10
Measuring secretion in chromaffin cells using electrophysiological and electrochemical methods.使用电生理和电化学方法测量嗜铬细胞中的分泌。
Acta Physiol (Oxf). 2008 Feb;192(2):173-84. doi: 10.1111/j.1748-1716.2007.01814.x. Epub 2007 Nov 16.